Introduction {#sec1_1}
============

Approximately 140,000 new cases of colorectal cancer are diagnosed annually in the United States \[[@B1]\]. Approximately 70% will undergo operative management and of those, about 40% will experience relapse \[[@B2]\]. Presented is a case study of a patient with over 17 years long-term survival of multiply recurrent metastatic colon carcinoma. In these 17 years, the patient has undergone four operations for tumor recurrence without any other adjuvant therapy besides the chemoradiation therapy completed after the time of initial diagnosis, with the latest recurrence being to the myocardium. In this case report, we wish to emphasize the integral role of surgery for recurrent disease and the unusual nature of the cardiac recurrence, and explore the implications and limitations of these multiple surgical interventions.

Case Report {#sec1_2}
===========

In 1992, a 60-year-old white female presented with hematochezia and change in bowel habits. Evaluation revealed rectosigmoid cancer without liver metastases on CT scan. Carcinoembryonic antigen (CEA) level was 28.7 ng/dl. She underwent low anterior resection. Pathology demonstrated well-differentiated adenocarcinoma, T3N1 (stage III). The patient underwent adjuvant therapy with 5-fluorouracil, levamisole and radiation therapy, completing therapy in 1993.

In July 1995, a CT scan for persistently elevated CEA demonstrated a lesion in the left lobe of her liver. MRI confirmed the left lobe lesion and was suspicious for a right lobe lesion as well. The patient underwent partial left and partial right hepatectomies in October 1995. Surgical pathology demonstrated recurrent adenocarcinoma with negative margins in both lesions. CEA levels returned to within normal range postoperatively. In the fall of 1999, an office visit physical exam revealed a palpable mass in her old incision site from the midepigastric region to the edge of the liver. CEA levels were also slightly elevated. Subsequent CT scans confirmed local tumor recurrence. The patient underwent right rectus muscle resection with partial antrectomy for adherent tumor. Margins were negative and the patient had an uneventful recovery. In September 2006, 16 years since her initial colon cancer diagnosis, a routine CEA measurement was again slightly elevated. Repeat CT scan demonstrated areas of abnormality in what would be the falciform ligament and in the abdominal wall just right of midline. A PET scan confirmed these areas of abnormality and indicated a more intrahepatic source. The patient underwent en bloc wedge liver resection, partial diaphragm resection, partial gastrectomy and partial right chest wall resection. No surgical margins were involved and the patient had an uneventful recovery.

In April 2009, the patient underwent reevaluation for elevated CEA. The heart border was abnormal on CT scan, and transesophageal echocardiogram showed a mass in the right atrioventricular groove. MRI confirmed this mass with some tumor involvement in the right atrium. The patient was asymptomatic. Repeat CT and PET scans at this time showed no other evidence of metastatic disease (**fig. [1](#F1){ref-type="fig"}**). In May 2009, the patient underwent cardiac surgery (**fig. [2](#F2){ref-type="fig"}**) and resection. The resection included right atrium and ventricular free wall with radical pericardectomy. Initial margins were involved, but were negative after additional resection. The defect was repaired with bovine pericardial patch, tricuspid valvuloplasty and bypass grafting. The patient had an uneventful recovery. A follow-up PET/CT scan 6 months after her cardiac surgery showed evidence for extension of the neoplastic disease in her left and right atria, confirmed by MRI. Gene markers confirmed tumor sensitivity to chemotherapy. The patient was started on oxaliplatin-based chemotherapy with bevacizumab. Last visit was November 2011 and she was on single agent bevacizumab without disease progression.

Discussion {#sec1_3}
==========

Approximately 140,000 new cases of colorectal cancer are diagnosed annually in the United States \[[@B1]\]. According to a study of the National Cancer Institute\'s Surveillance, Epidemiology, and End Results (SEER) database of approximately 140,000 people with colon cancer between 1999 and 2006, the 5-year survival rate for a stage III colon cancer patient is 70% \[[@B1]\]. The patient described in this case is now a 78-year-old woman with long-term survival from 17 years of recurrent colon cancer, initially stage III. She underwent low anterior resection with adjuvant chemoradiation therapy completed by 1993 and she has since undergone four more operations for metastases and local recurrences, including two liver resections, right chest wall and right abdominal wall resections, and most recently, cardiac resection. In this case, surgery was the best means of therapy for the recurrent disease at each time point and we suggest that the multiple surgical interventions are the main reason for this patient\'s long-term survival with metastatic colon adenocarcinoma. **Table [1](#T1){ref-type="table"}** shows the patient\'s course and interventions.

The latest curative-intent surgery undergone by this long-term colon cancer survivor has been cardiac resection, and this has resulted in the shortest disease-free interval of all her resections (6 months). There appear to be a total of ten case reports in the literature since 1982 of colorectal cancer metastases to the heart \[[@B3], [@B4], [@B5], [@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12]\]. Indeed, the literature suggests cardiac metastasis from colorectal cancer to be extremely rare, probably less than 2% of all cases based on autopsy series \[[@B13], [@B14]\]. Currently, there are no studies investigating the role of surgery in colorectal cancer cardiac metastases. Our patient underwent one cardiac resection and at 6 months follow-up was shown to have recurrence and extension of disease on PET imaging. Chemotherapy is the treatment of choice as no further cardiac resection is being considered.

When discussing colorectal cancer survival, several contributing factors are considered. One such factor is tumor biology, such as degree of differentiation, nodal involvement at presentation, CEA level, and mutations in k-ras and p53 \[[@B15]\]. Although these tumor markers are not routinely tested and the exact biology of this tumor is unknown, the patient likely has a less aggressive type of colon adenocarcinoma. If this tumor were more aggressive, recurrences would likely be widely metastatic, precluding further surgical intervention. As is seen in this case, however, all of her recurrences were either isolated metastases or resectable local recurrences, deeming surgical intervention appropriate therapy.

This particular patient did not benefit from improved chemotherapy as she was diagnosed in 1992 and treated with levamisole, a drug no longer used. She did, however, benefit from surgical intervention in 1995, 1999, 2006, and 2009. The patient also received consistent follow-up with her surgeon and oncologist which included frequent CEA measurements, as well as colonoscopies, CT, MRI and PET imaging when necessary that proved essential in detecting early recurrence amenable to curative-intent salvage surgery. The interesting surgical management in this case comes not at the onset of her disease, but throughout the multiple recurrences in the past 17 years, lastly the myocardial recurrence. Surgery remained the principal clinical intervention for this patient early on and she has benefited with long-term survival. Survival for stage IV colorectal cancer has been improving dramatically since 1998 for many reasons, including improvements in chemotherapy and more aggressive surgical resections \[[@B16]\]. At the times of this patient\'s metastatic disease resections, adjuvant therapy after metastasectomy was not considered standard of care, and the issue remains controversial \[[@B17], [@B18]\]. In the past 17 years, the patient has not undergone adjuvant chemotherapy after resection of recurrences. However, with her current cardiac recurrence, the patient underwent FOLFOX with bevacizumab and after being reevaluated for tumor sensitivity, bevacizumab only most recently. Current salvage chemotherapy regimens appear to improve survival for locally and distant recurrent disease \[[@B19]\].

This patient is an example of long-term metastatic colon cancer survival whose latest recurrence is in the heart, a very unusual place for colorectal metastatic disease. Surgery has been the primary intervention for her throughout her multiple recurrences. We would like to suggest that with a nonaggressive tumor biology and only locally recurrent disease, surgery can provide long-term survival for other colon cancer patients. Proper follow-up and patient selection will further ensure survival benefit from repeated surgical interventions. The role of new and active chemotherapy regimens in the adjuvant setting after resection of metastases remains an interesting area of future investigation.
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###### 

Clinical course of long-term survivor with metastatic colon cancer

  Date   Surgery for patient                                           Type of recurrence   Additional therapy received by patient
  ------ ------------------------------------------------------------- -------------------- -----------------------------------------
  1992   1\. Low anterior resection                                                         1\. 5-FU/levamisole; pelvic irradiation
  1995   2\. Bilobar liver resections                                  Metastatic           
  1999   3\. En bloc abdominal wall and gastric resection              Local                
  2006   4\. En bloc diaphragm, stomach, liver, chest wall resection   Metastatic           
  2009   5\. Cardiac resection                                         Metastatic           2\. FOLFOX
                                                                                            3\. FOLFOX + bevacizumab
  2010                                                                 Local                4\. Bevacizumab
                                                                                            
                                                                                            

5-FU = 5-Fluorouracil; FOLFOX = 5-FU, leucovorin, oxaliplatin.
